Jonathan Adly

4.4K posts

Jonathan Adly banner
Jonathan Adly

Jonathan Adly

@Jonathan_Adly_

Founder TJM labs | AI Engineer & Pharmacist | Building AI Solutions for Healthcare & Beyond

Delaware, USA Katılım Mart 2018
1K Takip Edilen1.4K Takipçiler
Max Marchione
Max Marchione@maxmarchione·
We need more compounding pharmacies. Who should I meet?
English
31
1
111
19.6K
Jonathan Adly
Jonathan Adly@Jonathan_Adly_·
@nikillinit Skill issue - we scaled to almost 5m arr with Linkedin outbound as main GTM motion
English
0
0
0
24
Nikhil Krishnan
Nikhil Krishnan@nikillinit·
Been having a bunch of convos with founders about marketing/sales. One common thing that’s come up is that cold outreach for startups (linkedin, email, etc.) seems to effectively be a completely dead channel now unless you have a large existing brand. This includes performance marketing through these channels Honestly seems like the ONLY way to get customers for B2B now -events - warm intros from advisor/venture firms - prosumer where employees are already using a free tier of the tool - Some form of channel partnership with a company that already has distribution (dicey depending on their reputation with customers)
English
33
4
155
25.8K
Jonathan Adly retweetledi
TJM Labs
TJM Labs@TJM_Labs·
We’re exhibiting at #AtriumX 2026 in Orlando next week! Looking forward to meeting pharmacy owners & innovators at this collaborative, action-focused event. Come by our booth to see how @TJMLabs is advancing solutions in pharmacy tech.
TJM Labs tweet media
English
0
1
1
181
Jonathan Adly retweetledi
TJM Labs
TJM Labs@TJM_Labs·
From the NCPA (@Commpharmacy) Multiple Locations Conference 🎥 TJM Labs VP of Sales Ross Miller joins Cole Thomas of @ConnexionRx to explain how TJM Labs helps pharmacies improve workflow and efficiency. #NCPA #HealthTech
English
0
1
2
142
Jonathan Adly
Jonathan Adly@Jonathan_Adly_·
@simonw Code used to be expensive, now it is cheap. Domain expertise and distribution are still expensive - and you can argue that they are more expensive now.
English
1
0
0
225
Simon Willison
Simon Willison@simonw·
I certainly don't think you can revisit vibe code a competitor to an existing platform - you still need to prove yourself in the market, earn customer trust and often generate network effects too. Those are still real moats that matter What's unclear to me is how much of an impact "it's expensive to produce the code that increments the features" no longer being true will have - I suspect quite a bit more than François is arguing here
English
16
1
83
14.9K
Simon Willison
Simon Willison@simonw·
I'm not so sure about this. Not all, but a lot of SaaS moats really do rely on an implementation complexity that's rapidly fading Take SAML for example - a classic example of a feature that is such a nightmare to implement that most SaaS startups delay as long as possible and then hire specialists If that implementation time drops from months to days, it's yet another little piece of moat that just got eroded away
François Chollet@fchollet

Cloning any random piece of SaaS is something that could already be done before agentic coding, and the economics of it haven't changed meaningfully. Before, writing the clone would cost 0.5-1% of the valuation of the legacy SaaS company. Now it might be 0.1%. It doesn't make a difference -- if you can pull it off profitably today you could also have done it profitably in the past. The code is a very small part of the process of making such a clone successful, and the reason legacy software has often bad UX is not because code was expensive to write.

English
66
14
399
74.7K
Jonathan Adly
Jonathan Adly@Jonathan_Adly_·
@_simonsmith There is a sweetspot when this will indeed be the case. Like you won’t do it with Figma so you 8 designers can save $299/month. But some shitty SOR that charges $300k to store records? Yea, it is worth it.
English
0
0
0
44
Simon Smith
Simon Smith@_simonsmith·
I work in a 1,600-person company where we did replace an expensive SaaS product with an internally created piece of software built by a senior engineer using AI. So this is happening. In our case, the software wasn’t just equivalent, but better for our needs. It eliminated features we didn’t need in the original, and added features specific to our use cases that the original didn’t have. We were also able to tightly integrate with our company operating system (think ERP+). Accordingly, I do think the SaaSpocalypse will happen. Jensen’s comments to me are wrong. Would an AI build a hammer if a hammer already existed? Absolutely it would, if the new hammer were more effective and efficient at hammering the specific types of nails the AI was using into the specific types of materials it was using. Most SaaS products aren’t a good fit for companies out of the box but must be configured. But now those companies can just create perfect bespoke software instead of configuring imperfect mass market software. This said, I do still think there will be a need for cloud services to serve all this bespoke software. Things like databases that are a single source of truth will be critical. So parts of the stack aren’t going away. We’ll still need places to safely and securely store and manage data. So it strikes me that a good pivot for software companies is to focus on data and APIs and documentation for AI to build with them. Those are raw materials that AI can use to create bespoke software, like buying wood and iron to build a custom hammer.
English
170
70
790
155.8K
Adam @ RepVue
Adam @ RepVue@thaAdamLittle·
Couple of GTM head to head battles I want to keep my eyes on in 2026: 1. Snowflake vs Databricks 2. Rippling vs Deel 3. Samsara vs Motive 4. Salesforce vs themselves 5. AWS vs GCP 6. Wiz vs Crowdstrike 7. Rubrik vs Cohesity 8. Figma vs Adobe 9. Monday dot com vs Asana Who did I miss?
English
74
12
479
74.9K
Jonathan Adly
Jonathan Adly@Jonathan_Adly_·
Great interview
John Collison@collision

Dave Ricks has been at @EliLillyandCo for 20% of its 150-year history. He came to the pub, poured his own Guinness, and gave us a 2-hour state of the pharma union: drug prices, clinical trials, patent clocks, the rise of generics, Chinese peptides, compounding pharmacies, the US healthcare system, and how the broad success of GLP-1s have transformed Lilly's business. If you've never heard Dave speak before, you're in for a treat. Timestamps: 00:00 Intro 05:08 Making R&D decisions 10:11 Clinical trials 24:59 Drug pricing 32:43 Stimulating more R&D 45:16 Pros and cons of US healthcare 58:20 New pharma business models 01:05:53 Stripe + enterprises 01:07:00 China 01:16:31 Generics 01:22:37 GLP-1s 1:37:43 r/Peptides 01:41:25 LillyDirect 01:46:35 Why do investors love LLY?

English
0
0
2
416
Jonathan Adly retweetledi
a16z speedrun 🧊
a16z speedrun 🧊@speedrun·
Ben Horowitz on the brilliant advice you often get from investors
a16z speedrun 🧊 tweet media
English
110
351
6.5K
935.6K
Jonathan Adly retweetledi
TFTC
TFTC@TFTC21·
The most broken system in America... Health insurance
English
70
329
1.1K
324.4K
Jonathan Adly retweetledi
Braelyn ⛓️
Braelyn ⛓️@braelyn_ai·
my hottest take is that conda is objectively better than uv 1. conda is short for anaconda, which is a type of snake. guess what, so is a python 2. used primarily by academia and they are famously smart people, so they must know something we dont 3. "conda activate" makes you feel like you're commanding a tank. "uv run" sounds like you're doing laundry 4. it takes 45 minutes to resolve dependencies which gives you time to smash another white monster and watch youtube at work
English
184
167
3.3K
188.2K